Focus Partners Wealth
VIR icon

Focus Partners Wealth’s Vir Biotechnology VIR Stock Holding History

Focus Partners Wealth’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,088
Closed -$90.4K – 2975
2026
Q1 		$90.4K Buy
+10,088
New +$80.4K ﹤0.01% 2526
2025
Q3 		– Sell
-18,447
Closed -$93K – 2318
2025
Q2 		$93K Sell
18,447
-870
-5% -$4.67K ﹤0.01% 1949
2025
Q1 		$125K Buy
19,317
+2,566
+15% +$22.8K ﹤0.01% 1800
2024
Q4 		$123K Sell
16,751
-29,683
-64% -$234K ﹤0.01% 1780
2024
Q3 		$348K Buy
+46,434
New +$403K ﹤0.01% 1282

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Focus Partners Wealth's VIR Position: Q2 2026 in Review

Focus Partners Wealth sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 10,088 shares — an estimated $90.4K sold.

Focus Partners Wealth first reported a position in VIR in Q3 2024 and held it in 5 quarters. The position peaked at $348K in Q3 2024. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Focus Partners Wealth reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 10,088 Vir Biotechnology shares in Q2 2026, an estimated $90.4K.
  • Focus Partners Wealth first reported a position in Vir Biotechnology in Q3 2024 and held it in 5 quarters.
  • Focus Partners Wealth's Vir Biotechnology position peaked at $348K in Q3 2024.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.